Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer.

Hiltbrunner, Stefanie; Spohn, Meta-Lina; Wechsler, Ramona; Akhoundova, Dilara; Bankel, Lorenz; Kasser, Sabrina; Bihr, Svenja; Britschgi, Christian; Maathuis, Marloes H; Curioni-Fontecedro, Alessandra (2022). Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. Cancers, 14(1) MDPI AG 10.3390/cancers14010075

[img]
Preview
Text
cancers-14-00075.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (821kB) | Preview

Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects and not all patients benefit from the treatment. We conducted a comprehensive statistical analysis to identify promising (bio-)markers for treatment response. We analyzed retrospective data from NSCLC patients treated with ICIs in first- or further-line therapy settings at the University Hospital Zurich. We investigated 16 possible prognostic markers with respect to overall survival, tumor size reduction, and the development of an immune-related adverse event (irAE) and assessed the robustness of our results. For the further-line patient group, the most significant result was that increased basophil counts were associated with increased odds of tumor size reduction within three months and with the development of an irAE. For the first-line patient group, the most significant results were that increased lymphocyte counts, the histology of adenocarcinoma, and the intake of non-steroidal anti-rheumatic drugs (NSAR) were associated with decreased hazards of dying. Our study yielded new hypotheses for predictive (bio-)markers for response to ICIs in NSCLC patients. The possibly beneficial role of high basophil counts is a particularly interesting finding. Our results should be tested on independent data in a prospective fashion.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Akhoundova Sanoyan, Dilara

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2072-6694

Publisher:

MDPI AG

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

18 Nov 2022 15:24

Last Modified:

05 Dec 2022 16:28

Publisher DOI:

10.3390/cancers14010075

PubMed ID:

35008239

Uncontrolled Keywords:

basophils biomarker immune checkpoint inhibitors non-small cell lung cancer statistical analysis

BORIS DOI:

10.48350/174913

URI:

https://boris.unibe.ch/id/eprint/174913

Actions (login required)

Edit item Edit item
Provide Feedback